Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.

Journal Article (Journal Article)

A successful vaccine vector for human immunodeficiency virus type 1 (HIV-1) should induce anti-HIV-1 T-cell immune responses at mucosal sites. We have constructed recombinant Mycobacterium bovis bacillus Calmette-Guérin (rBCG) expressing an HIV-1 group M consensus envelope (Env) either as a surface, intracellular, or secreted protein as an immunogen. rBCG containing HIV-1 env plasmids engineered for secretion induced optimal Env-specific T-cell gamma interferon enzyme-linked immunospot responses in murine spleen, female reproductive tract, and lungs. While rBCG-induced T-cell responses to HIV-1 envelope in spleen were lower than those induced by adenovirus prime/recombinant vaccinia virus (rAd-rVV) boost, rBCG induced comparable responses to rAd-rVV immunization in the female reproductive tract and lungs. T-cell responses induced by rBCG were primarily CD4(+), although rBCG alone did not induce anti-HIV-1 antibody. However, rBCG could prime for a protein boost by HIV-1 envelope protein. Thus, rBCG can serve as a vector for induction of anti-HIV-1 consensus Env cellular responses at mucosal sites.

Full Text

Duke Authors

Cited Authors

  • Yu, J-S; Peacock, JW; Jacobs, WR; Frothingham, R; Letvin, NL; Liao, H-X; Haynes, BF

Published Date

  • July 2007

Published In

Volume / Issue

  • 14 / 7

Start / End Page

  • 886 - 893

PubMed ID

  • 17507541

Pubmed Central ID

  • PMC1951062

International Standard Serial Number (ISSN)

  • 1556-6811

Digital Object Identifier (DOI)

  • 10.1128/CVI.00407-06


  • eng

Conference Location

  • United States